Filter Results
:
(521)
Show Results For
-
All HBS Web
(521)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
Show Results For
-
All HBS Web
(521)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
- 07 Feb 2017
- First Look
First Look at New Research: February 7
case:https://cb.hbsp.harvard.edu/cbmp/product/517027-PDF-ENG Harvard Business School Case 617-022 Alnylam Pharmaceuticals: Building Value from the IP Estate (B) The leader of a pioneering biotech company in the siRNA space weighs his...
View Details
Keywords:
Sean Silverthorne
- 03 May 2011
- First Look
First Look: May 3
Business Model Gary P. Pisano, Ryan Johnson, and Carin-Isabel KnoopHarvard Business School Case 611-046 In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this...
View Details
Keywords:
Sean Silverthorne
- 01 Dec 2010
- News
This Is What I Do
thus deserve our support.” The MJFF raises about $50 million a year. There are prominent backers, such as Google’s Sergey Brin and his wife, Anne Wojcicki, but nearly 55,000 other people made contributions last year. To date the MJFF has supported about ninety View Details
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
asking, is this the right business model? But there are no answers. The market and technology are constantly changing," Riesenfeld remarks. Important Sounding Board The biotech industry presents similar challenges in a space littered with...
View Details
- 01 Jun 2011
- News
The Best-Laid Plans
deals with Bed Bath & Beyond, Frontier Airlines, and Johnson & Johnson. “You’re always asking, is this the right business model? But there are no answers. The market and technology are constantly changing,” Riesenfeld remarks. The biotech...
View Details
- 01 Mar 2011
- News
Making Their Way
firm. But when her father fell ill in 1986, the Brownells decided to return to Detroit to help with the family enterprise founded by her great-grandfather. As things turned out, Brownell’s father recovered and was able to continue with the company. But Brownell, who in...
View Details
- 01 Jun 2007
- News
Mission Possible
“Rudy contends that if we can identify the other ten or twelve genes that are players, we can give the biotech industry so many more shots to come up with a therapy,” explains McCance, who, along with his cofounders, is privately...
View Details
- 12 May 2009
- First Look
First Look: May 12, 2009
this situation, donations are likely to decline, investment surplus has declined and biotech partners are challenged to finance joint projects as well as their own operations. Beall is striving to find a cure for cystic fibrosis while...
View Details
Keywords:
Martha Lagace
- 01 Sep 2009
- News
E Ink’s Wild Ride
that required a massive amount of investment before it could take off,” says Yoffie, who served on E Ink’s board from 1999 to 2004. “The truism is that getting to that point takes longer and costs more money than the most pessimistic forecast. It’s a very similar...
View Details
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Download the paper: http://www.hbs.edu/research/pdf/09-099.pdf Cases & Course MaterialsAvid Radiopharmaceuticals: The Venture Debt Question Harvard Business School Case 809-086 The CEO of a promising biotech company must decide how...
View Details
Keywords:
Martha Lagace
- 01 Jun 2018
- News
Up by the Roots
establishing a platform for building relationships among the relevant actors—to be a replicable model of ecosystem development that could be applied anywhere, and to any industry. (At the moment, she is attempting to strike gold twice in one place by boosting New...
View Details
- 04 Jun 2007
- Research & Ideas
Is Health Care Making You Better—or Dead?
technological innovation, which is how the biotechs and some of the medical devices can get through these hurdles. But for a health service innovation, the payment hurdles are so massive it's masochistic. Then if you go into competition...
View Details
- 01 May 2007
- First Look
First Look: May 1, 2007
drug development process; threats from biotech and generics competitors; pharmaceutical manufacturing, selling, and marketing; and pharmaceutical consumption in Europe, the third world, and the U.S. Merck and Pfizer are analyzed in-depth...
View Details
Keywords:
Sean Silverthorne
- 28 Apr 2009
- First Look
First Look: April 28, 2009
testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful...
View Details
Keywords:
Martha Lagace
- 21 Apr 2009
- First Look
First Look: April 21, 2009
this case: http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807106 Note on Biotech Business Development Harvard Business School Note 807-032 Describes the business development process in biotechnology...
View Details
Keywords:
Martha Lagace
- Web
Podcast - Managing the Future of Work
technician. We have contracts with the United States government. We’re working on the vaccine response and tracking. We also provide lab technicians that are working with major pharmaceutical and biotech companies on breakthrough drugs....
View Details
- 28 Aug 2012
- First Look
First Look: August 28
determining a new venture's future alliance formation diminishes as the new venture's prominence in alliance networks increases. Evidence from biotech alliances between new ventures and established companies provides support for our...
View Details
Keywords:
Sean Silverthorne
- 12 Jul 2021
- News
Alumni Confront the COVID-19 Crisis
PYMNTS.com. (Readers who know of groups in need of PPE can email Miller at anne@projectn95.org.) NOVEMBER 23 Cambridge-based biotech Moderna, led by CEO Stephane Bancel (MBA 2000, AMP 170), released promising results on the coronavirus...
View Details
- Web
Print View - Course Catalog
tech ventures, including those pursuing frontier clean energy, material science, biotech and aerospace technologies. We will have case protagonists and guests in every class including tough tech entrepreneurs, investors and domain experts...
View Details